At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Quinagolide 360 µg +3 moredrug
Likely dose
Quinagolide 360 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Assessing the Efficacy, Safety and Dose-response of Quinagolide Extended-release Vaginal Rings Administered Sequentially for 4 Menstrual Cycles in Women With Moderate to Severe Endometriosis-related Pain
In Brief
A Phase 2 clinical trial evaluating Quinagolide 360 µg, Quinagolide 720 µg, and 2 other interventions for Endometriosis-related Pain. Completed, enrolled 22 participants across 43 sites.
Detailed Summary
To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis-related Pain
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartDec 2018
Primary CompletionFeb 2022
TodayJul 2026
First PostedOct 2, 2018
Enrollment StartDec 26, 2018
Primary CompletionFeb 14, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.8 years ago
Interventions
Quinagolide 360 µgdrug
Vaginal ring containing quinagolide 360 µg for daily releases
Quinagolide 720 µgdrug
Vaginal ring containing quinagolide 720 µg for daily releases
Quinagolide 1080 µgdrug
Vaginal ring containing quinagolide 1080 µg for daily releases
Placebodrug
Matching placebo